Stock Challenges Persist for Evaxion Biotech Evaxion Biotech’s stock has hit a 52-week low of $2.22, reflecting an 87% decline over the past year. Despite financial challenges, including a weak health score, analysts forecast a nearly 50% revenue growth for FY2024, supported by recent capital raises and a promising cancer vaccine pipeline.34